UK markets open in 5 hours 30 minutes

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
7.53-0.08 (-1.05%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close7.61
Bid7.63 x 1400
Ask7.64 x 3100
Day's range7.52 - 8.08
52-week range0.25 - 18.77
Avg. volume14,914,279
Market cap1.497B
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)-0.27
Earnings date04 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est7.90
  • Motley Fool

    Is Ocugen Worth Another Look After Good News for COVID Vaccine Covaxin?

    The World Health Organization is expected to soon grant emergency use listing for COVID-19 vaccine Covaxin. While the vaccine was developed by Bharat Biotech, Ocugen (NASDAQ: OCGN) has the rights to market Covaxin in the U.S. and in Canada. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Ocugen stock is worthy of another look by investors if Covaxin receives EUL.

  • Motley Fool

    Could This News Spark a Turnaround for Ocugen?

    Ocugen (NASDAQ: OCGN) shares were flying high earlier this year. The company signed a deal with India's Bharat Biotech for co-commercialization rights to its coronavirus vaccine candidate in the U.S. The Bharat product was close to market. Since then, Ocugen learned it wouldn't win the right to sell the vaccine in the U.S. as soon as it had hoped.

  • Motley Fool

    Why COVID Vaccine Stocks BioNTech, Moderna, and Novavax Are Sliding While Ocugen Is Rising

    Investors are nervous about a Food and Drug Administration advisory panel meeting and optimistic about a World Health Organization decision.